Qualigen Therapeutics, Inc. announced the addition of pharmaceutical executive Amy Broidrick to the company's Board of Directors. Ms. Broidrick's background includes key roles in the successful worldwide launches and marketing of VYTORIN™, Zetia™ and Celebrex™. Since 2016, Ms. Broidrick has served as Senior Vice President, Head of Corporate Development at Viking Therapeutics with responsibility for building and implementing the US and global corporate and business development function. Before that, she was Vice President, Head of Global Marketing Excellence and Business Innovation with EMD Serono (part of Merck KGaA), where she led global and country brand and launch planning, and led strategic transformation initiatives.